BIOMAT Database Logo BIOMAT Database Logo

Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia. 1987

D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemia.
June 1987, Seminars in oncology,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
[VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
January 1984, Sangre,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia.
June 1987, Seminars in oncology,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
October 1990, Cancer,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia.
April 2012, Mymensingh medical journal : MMJ,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia.
October 1985, European journal of cancer & clinical oncology,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
[Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
October 1988, Anales espanoles de pediatria,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma.
April 1987, European journal of cancer & clinical oncology,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
January 2014, Medicinski pregled,
D Hoelzer, and E Thiel, and H Löffler, and T Büchner, and A Ganser, and G Heil, and E Kurrle, and H Heimpel, and P Koch, and T Lipp
Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
March 1980, Cancer,
Copied contents to your clipboard!